Eckert & Ziegler at a Glance German Equity Forum Frankfurt 26 - - PowerPoint PPT Presentation

▶
eckert amp ziegler
SMART_READER_LITE
LIVE PREVIEW

Eckert & Ziegler at a Glance German Equity Forum Frankfurt 26 - - PowerPoint PPT Presentation

Apr 17, 2023 480 likes •774 views

Eckert & Ziegler at a Glance German Equity Forum Frankfurt 26 November 2019 Dr. Andreas Eckert CEO 1 Gl Glob obally ally Po Positi sition oned ed for for 25 25 Years Years Nich Ni che Play Player i er in Isoto n Isotope

slide-1
SLIDE 1

1

Eckert & Ziegler at a Glance

German Equity Forum Frankfurt 26 November 2019

  • Dr. Andreas Eckert

CEO

slide-2
SLIDE 2

2

Berlin

Gl Glob

  • bally

ally Po Positi sition

  • ned

ed for for 25 25 Years Years Ni Nich che Play Player i er in Isoto n Isotope pe M Mark arket et

Geräte

Rohstoffe/ API Rohstoffe/ API

LDR LDR HDR

Raw materials API Projects/ API

Pharmaceuticals (RADIOPHARMA)

Synthesis Devices

EUR 80 Mio. 59% EUR 20 Mio. 16% EUR 33 Mio. 25%

Strong 3rd Half Year 2019 with Revenues of € 133 Mio. (FY 2018: € 169 Mio.)

Industrial Components (ISOTOPE PRODUCTS)

Production Services Trading Disposal

Cancer Radiation

(RADIATION THERAPY)

Implants Applicators Devices

Slides for Illustration – The spoken word shall be binding

slide-3
SLIDE 3

3

Fro From Ja Janu nuary ary 1st 1st 2020: 2020: Med Medical Seg ical Segmen ment t Po Pool

  • l

Geräte

Rohstoffe/ API Rohstoffe/ API

LDR LDR HDR

Raw materials API Projects/ API

Pharmaceuticals (RADIOPHARMA)

Synthesis Devices

Industrial Components (ISOTOPE PRODUCTS)

Production Services Trading Disposal

Cancer Radiation

(RADIATION THERAPY)

Implants Applicators Devices

From 1.1.2020: MEDICAL

Slides for Illustration – The spoken word shall be binding

Engineering

slide-4
SLIDE 4

800 800 Employ Employee ees (Head (Headco coun unts ts) ) 19 19 Site Sites s Wo World rldwide wide

4

Result Q3-2019

(Mio. EUR)

Revenues 133,2 Net Income 18,8

2%

2 44% 41% 9% 6% EUROPE AMERICA ASIA MIDDLE EAST & AFRICA

Slides for Illustration – The spoken word shall be binding

slide-5
SLIDE 5

Rev Reven enue ues of

  • f Abo

About ut € 170 Mio.

  • Mio. in

in 2018 2018

in Mio. EUR

5

  • Incl. discontinued and continued operations

18% organic growth in 2018

0,13 1 2 4 6 6 8 10 24 33 31 29 36 42 50 54 71 101 111 116 120 117 127 140 138 145 169 20 40 60 80 100 120 140 160 180 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018

Slides for Illustration – The spoken word shall be binding

slide-6
SLIDE 6

Rev Reven enue ues pe per r Seg Segmen ment

Q3 Q3-2019 2019 vs vs. . Q3 Q3-2018 2018, Mio. Euro

6

Total Revenues of 133,2 Mio. EUR in Q3-2019 (Q3-2018: Euro 123,8 Mio.) + 8% in Q3-2019

Slides for Illustration – The spoken word shall be binding

slide-7
SLIDE 7

Net Net Inco Income me

Q3 Q3-2019 2019 vs.

  • vs. Q3

Q3-2018 2018 in M in Mio. E

  • io. EUR

UR

7

Net Income of 18,8 Mio. EUR in Q3-2019 (Q3-2018 :13,0 Mio. EUR) + 45% in Q3-2019

Folie nur zur Illustration – es gilt das gesprochene Wort

slide-8
SLIDE 8

Balan Balance ce She Sheet et

as as of

  • f 30

30.09.20 .09.2019 19, , in Mio. EUR

8

  • Cash and cash equivalents at period end of 71 Mio. EUR
  • Debt Free (except accounted leasing according to IFRS 16)
  • Equity Ratio of 53%

Cash 71 Equity 131 Recievables 25 Minority Interests 6 Inventory 31 Loans 18 Intangible Assets 70 Accruals/Provisions 66 Fixed Assets 38 Other Short Term Payables 31 Others 25 Other Long Term Payables 6 Total Activ 259 Total Passiv 259

Slides for Illustration – The spoken word shall be binding

slide-9
SLIDE 9

Cashflow Cashflow in in Q3

Q3-20 2019 19, , in Mio. EUR

9

EBITDA of 36,6 Mio. EUR

Slides for Illustration – The spoken word shall be binding

slide-10
SLIDE 10

Net Net Liqu Liquidity idity in in Q3 Q3-2019, 2019,

in Mio. EUR

10

+10 mm EUR for treasury shares

Slides for Illustration – The spoken word shall be binding

2014 2015 2016 2017 2018 Q3-2019 Liquidity 22 31 37 58 54 71 Debt 19 16 12 2 Net Liquidity 3 15 25 56 54 71 10 20 30 40 50 60 70 80 10 20 30 40 50 60 70 80 In Mio. EUR

slide-11
SLIDE 11

Sha Share re Per Performa formanc nce e and and Dividen Dividend d in in EUR/Share EUR/Share

11

0,60 0,60 0,60 0,66 0,8 1,2

0,50 0,60 0,70 0,80 0,90 1,00 1,10 1,20 20 40 60 80 100 120 140 160 180 2014 2015 2016 2017 2018 2019

Dividende in EUR / Aktie EUR/Aktie

Slides for Illustration – The spoken word shall be binding

slide-12
SLIDE 12

Ov Overview erview

12

  • Theranostics
  • Interventional Radiology
  • Outlook
slide-13
SLIDE 13

Str Strat ateg egy / Gr / Growt

  • wth

h Opp Oppor

  • rtu

tunities nities

13

About tigers, dragons, and other creatures

slide-14
SLIDE 14

Our Our Top Topics ics

14

  • Poor man‘s PET – Theranostics
  • Dying decently – Interventional Radiology
slide-15
SLIDE 15

Poor Man‘s PET: Capital Exp Expen en- ditu diture res Bec Become

  • me Con

Consu sumab mables les

  • A vision comes true
  • Eckert & Ziegler pionieers first pharmaceutically approved

gallium generator worldwide

  • No need for CAPEX an expensive cyclotron
  • Transfer of an investment into consumables

15

Purchase costs incl. Radiopharmacy 6 bis 8 Mio. EUR plus staff

slide-16
SLIDE 16

Comp Complex lex Sup Supply ply Cha Chains ins Bec Become

  • me Obs

Obsolet

  • lete

Own Cyclotrons

  • Berlin-Adlershof
  • Bonn
  • Vienna (Seibersdorf)
  • new: Warsaw

Exklusive Distribution

  • Karlsruhe
  • Bad Berka

16 Folie nur zur Illustration – es gilt das gesprochene Wort

slide-17
SLIDE 17

Globa Global l Mar Marke ket t Ent Entra ranc nce

  • f
  • f the

the Gen Gener erat ator

  • r
  • Opens up precision oncology for the bulk of hospitals
  • Makes the treatment of niche indications in smaller

clinics more attractive

Slides only for illustration – the spoken word shall be binding 17

slide-18
SLIDE 18

Pre Precision cision Onc Oncolog

  • logy

Still Still at at the the Beginning Beginning

Advantage

  • Therapy only for patients

who respond to the diagnostic

– saves unnecessary expenses – saves unnecessary patient stress

  • Strengthens nuclear

physicians as a distribution channel

18

Neuroendocrine tumors Prostate, Renal cancer Non-Hodgkin-Lymphoma Gastro THERAPY (Lu-177) DIAGNOSIS (Ge-68)

Slides for Illustration – The spoken word shall be binding

slide-19
SLIDE 19

But But: : Exp Expan ansion sion of

  • f Indica

Indication tion is is Like Likely ly to to Come Come

19

https://clinicaltrials.gov/ct2/results?term=lutetium&age_v=&gndr=&type=&rslt=&phase=1&phase=2&Search=Apply

Clinical studies with Lu-177 acc. to FDA, Phase II or higher, as of May 2019

Slides for Illustration – The spoken word shall be binding

slide-20
SLIDE 20

Numb Number er of Diagn

  • f Diagnos
  • ses

es Cou Could ld Sud Sudde denly nly Incr Increa ease se

  • Diagnosis is key to therapy details
  • Retreatment likely

–Diagnosis and therapy control may add up to ø 2 scans/ patient?

20

https://www.itnonline.com/content/theragnostics-reports-positive-clinical-trial-results-prostate-cancer-study

slide-21
SLIDE 21

INTE INTERVE RVENTI NTIONAL ONAL RADIOLOG RADIOLOGY

Dying decently

Slides only for illustration – the spoken word shall be binding 21

slide-22
SLIDE 22

Principle Principle of Invert

  • f Inverted

ed Tree Tree

Pellets/spheres are proprietary Radioactive loading done by Eckert & Ziegler

slide-23
SLIDE 23

Hug Huge Numb Number er of

  • f Cas

Cases es in China in China At Attr trac active tive Reimbu Reimburs rsemen ement

23

Age-standardized incidence rates of hepatocellular carcinoma per 100,000 populations at risk, in different regions of world (Source: GLOBOCAN 2002).

China 280,000 men 100,000 women ~380,000 cases per year (!)

Reimbursement China ~ 11,000 US$/ patient

Slides for Illustration – The spoken word shall be binding

slide-24
SLIDE 24

Numerou Numerous Medica s Medical l Device Device Co Compa mpanies nies Sta Start the rt their ir own

  • wn P

Prog rograms rams

and much more….

Slides for Illustration – The spoken word shall be binding

slide-25
SLIDE 25

Fitt Fitting ing Well Well into into the the Pictu Picture re

  • Bayer/ ALGETA

– (2014)

  • IPSEN/ OPS

– 2015

  • NOVARTIS/ AAA

– (2017)

  • NOVARTIS/ Endocyte

– 2017

  • GCP/ SIRTEX

– June 2018

  • Boston Scientific/ BTG

– November 2018

  • Bracco/ Blue Earth

– April 2019

2,1 Mrd. USD 2,1 Mrd. USD 4,0 Mrd. USD 0,1 Mrd. USD

Ra-223 Lu-177

1,4 Mrd. USD

Ge-68 Y-90 Ge-68 Y-90

4,2 Mrd. USD 0,5 Mrd. EUR

F-18 Isotop

Slides for Illustration – The spoken word shall be binding

slide-26
SLIDE 26

M&A M&A Acti Activiti vities es Fu Full ll Spe Speed ed Ahea Ahead d in 2 in 201 019 9 as We as Well ll

  • Bayer/ ALGETA

– (2014)

  • IPSEN/ OPS

– 2015

  • NOVARTIS/ AAA

– (2017)

  • NOVARTIS/ Endocyte

– 2017

  • GCP/ SIRTEX

– Juni 2018

  • Boston Scientific/ BTG

– November 2018

  • Bracco/ Blue Earth

– April 2019

2,1 Mrd. USD 2,1 Mrd. USD 4,0 Mrd. USD 0,1 Mrd. USD

Ra-223 Lu-177

1,4 Mrd. USD

Ge-68 Y-90 Ge-68 Y-90

4,2 Mrd. USD 0,5 Mrd. EUR

F-18 Isotop

Slides for Illustration – The spoken word shall be binding

slide-27
SLIDE 27

Thank Thank you you!

27 Slides for Illustration – The spoken word shall be binding

slide-28
SLIDE 28

Fina Financ ncial ial Calen Calenda dar / I / IR-Con Conta tact ct

ISIN DE0005659700 Reuters EUZ.DE

28

31.03.2020 Publication FY2019 12.05.2020 Quarterly Report I May 2020 Spring Conference in Frankfurt 17.06.2020 Annual General Meeting in Berlin 13.08.2020 Quarterly Report II 10.11.2020 Quarterly Report III Eckert & Ziegler AG Karolin Riehle Investor Relations & PR Robert-Rössle-Str. 10 D-13125 Berlin

  • Tel. +49 30 94 10 84-138

Fax +49 30 94 10 84-112 karolin.riehle@ezag.de www.ezag.com

Slides for Illustration – The spoken word shall be binding